<DOC>
	<DOCNO>NCT00421421</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety dutasteride reduce relapse rate Acute Urinary Retention ( AUR ) , include reduction surgical intervention benign prostatic hyperplasia ( BPH ) , patient receive 6 month treatment dutasteride ( 0.5mg daily ) follow single episode AUR follow successful Trial Without Catheter compare placebo .</brief_summary>
	<brief_title>Effects Of Dutasteride On Risk Reduction Of Acute Urinary Retention Relapse Following Trial Without Catheter</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Urinary Retention</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<criteria>Able read , write understand instruction relate study procedure able give write informed consent Able swallow retain oral medication Had single , spontaneous episode AUR relate BPH drain volume 500 1500ml Had successful TWOC ( define successful patient return satisfactory void within first 24 hour catheter removal without recatheterisation ) follow 2 3 day treatment alpha blocker ( preferably alfuzosin 10mg OD ) pre TWOC follow seven day treatment alpha blocker ( preferably alfuzosin 10mg OD ) post TWOC . Able randomise within 7 day successful TWOC Prostate volume ( PV ) less 30cc great 80cc measure via Trans Rectal Ultrasound ( TRUS ) either time hospitalisation part screen / randomisation visit Previous episode AUR prior current episode AUR relate BPH i.e . postoperative retention follow major abdominal / pelvis surgery Previous prostate urethral surgery Previous positive prostate biopsy Any cause BPH may result urinary symptom change flow rate . Any unstable coexisting medical condition Previous 5ARI use Previous alpha blocker treatment study mandate 2 3 day pre 7 day post TWOC period alpha blocker ( preferably alfuzosin 10mg OD ) Use prohibit med ( e.g . 5ARI 's , anabolic steroid include testosterone , drug antiandrogenic property ) Liver enzyme ( ALT , AST , ALP ) time hospitalisation / screen visit great 2 x ULN bilirubin time hospitalisation / screen visit great 1.5 x ULN . Serum creatinine time hospitalisation / screen visit great 1.5 x ULN Treatment investigational product within 30 day prior first dose study medication History current evidence alcohol drug abuse within last 12 month Prostate Specific Antigen ( PSA ) great 20ng/ml Use suprapubic catheterisation fail urethral catheterisation Neurogenic bladder dysfunction , confirm suspect , irrespective etiology Isolated bladder neck disease Acute chronic prostatitis Confirmed suspect urethral stricture Known bladder stone Clot retention secondary haematuria cause Patient unwilling use condom sexual intercourse</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Acute Urinary Retention</keyword>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>Trial Without Catheter</keyword>
</DOC>